<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02527629</url>
  </required_header>
  <id_info>
    <org_study_id>2015- 01, 20.07.2015</org_study_id>
    <secondary_id>Grant Agreement No: 643597</secondary_id>
    <nct_id>NCT02527629</nct_id>
  </id_info>
  <brief_title>Aortic Replacement Using Individualised Regenerative Allografts - ARISE (the &quot;Surveillance&quot;)</brief_title>
  <acronym>ARISE</acronym>
  <official_title>Aortic Replacement Using Individualised Regenerative Allografts: Bridging the Therapeutic Gap - ARISE (the &quot;Surveillance&quot;)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>corlife</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hannover Medical School</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Leiden University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Azienda Ospedaliera di Padova</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Clinic of Barcelona</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Royal Brompton &amp; Harefield NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Universitaire Ziekenhuizen Leuven</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Heinrich-Heine University, Duesseldorf</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Vienna General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>corlife</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation of decellularized human heart valves for aortic heart valve replacement in
      comparison to current valve substitutes.

      Safety endpoints include cardiovascular adverse events, time to re-operation, re-intervention
      and explantation.

      Efficacy endpoints include freedom from valve dysfunction and hemodynamic performance.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, non-randomized, single-arm, multi-centre surveillance study to be
      conducted in Europe.

      The Surveillance is designed as a study, where

        -  ARISE AV is prescribed in the usual manner in accordance with the terms of the approval.

        -  Assignment of the patient to a particular therapeutic strategy is not decided in advance
           by this Surveillance Protocol but falls within current practice and the prescription of
           ARISE AV is clearly separated from the decision to include the patient in the
           Surveillance.

        -  No additional diagnostic or monitoring procedures shall be applied to the patients.

        -  and epidemiological methods shall be used for the analysis of collected data.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Anticipated">March 2019</completion_date>
  <primary_completion_date type="Anticipated">January 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Cardiovascular Adverse Reactions (AR)</measure>
    <time_frame>up to 24 months</time_frame>
    <description>Rate of cardiovascular AR, e.g. all‐cause mortality, major stroke, life‐threatening (or disabling) bleeding, acute kidney injury—stage 3 (including renal replacement therapy), peri‐procedural myocardial infarction, major vascular complication, repeat procedure for valve‐related dysfunction (surgical or interventional therapy).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Freedom from valve dysfunction at end of the study</measure>
    <time_frame>up to 24 months</time_frame>
    <description>Echocardiographic studies should be obtained and analyzed at discharge and at 3, 6 Months and at annual follow-ups. The requested variables include peak and mean systolic gradient, using pw and cw doppler, in the left ventricular outflow tract, respective the aortic valve. The echo evaluation (videotape or CD) should remain at the Surveillance site, but be available to corlife Surveillance personnel upon request. The MRIs will be analyzed by the MRI Core Laboratory at Medical School in Hannover for potential valvular stenosis, via phase contrast flow measurements in the aorta and for valvular competence, via phase contrast flow measurements and by ventricular volumetry. MRI cine images will be used to visualize the Surveillance valve in patients with poor echocardiographic windows.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of composite blood parameters</measure>
    <time_frame>up to 24 months</time_frame>
    <description>The following data should be collected: Hb, LDH, Haptoglobin, CRP, Leukocytes. Blood studies should be performed within 7 days preoperatively and at discharge. Blood data will support the absence/presence of related AR. For example, haemolysis should be reported as an adverse event if anaemia is present; however, in the absence of anaemia, haemolysis will be considered to be compensated and does not require reporting. Time to events, such as death, reoperation including explantation will be evaluated for those outcomes, calculated from the date of operation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reoperation and / or death</measure>
    <time_frame>up to 24 months</time_frame>
    <description>Time to events, such as death, reoperation including explantation will be evaluated for those outcomes, calculated from the date of operation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of composite valve measures</measure>
    <time_frame>up to 24 months</time_frame>
    <description>Diameters of ARISE AV at end of the Surveillance will be analyzed in comparison to diameters at implantation and to age matched reference values. Preoperative non-invasive data on left ventricular size and function, such as left ventricular end diastolic, end systolic volume, ejection fraction and ventricular mass will be derived from MRI and compared to postoperative status.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Heart Valve Disease</condition>
  <arm_group>
    <arm_group_label>Decellularized human valves</arm_group_label>
    <description>Aortic heart valve replacement</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Decellularized human heart valves</intervention_name>
    <description>Decellularized human aortic heart valves</description>
    <arm_group_label>Decellularized human valves</arm_group_label>
    <other_name>Arise Aortic Valve (AV)</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with severe aortic valve disease and the indication for aortic valve replacement
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        i. Indication for aortic valve replacement according to current medical guidelines in
        valvular heart disease

        ii. Informed consent of legal guardians or patients, assent of patients

        Exclusion Criteria:

        i. The patient has not provided Surveillance informed consent.

        ii. The patient shall not suffer from:

          -  generalized connective tissue disorders (eg, Marfan syndrome), or .

          -  active rheumatic disorders, or

          -  severe asymmetric calcification of the valve ring.

        iii. The coronary arteries of the patient shall not be in abnormal position or heavily
        calcified.

        iv. Patients shall not show hypersensitivity against sodium dodecyl sulphate (SDS), sodium
        desoxycholate (SDC), human collagen (or other elastic fibers) or Benzonase®.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Axel Haverich, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hannover Medical School</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Samir Sarikouch, PD Dr.</last_name>
    <role>Study Director</role>
    <affiliation>Hannover Medical School</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Samir Sarikouch, PD MD</last_name>
    <phone>0049511532</phone>
    <phone_ext>5567</phone_ext>
    <email>sarikouch.samir@mh-hannover.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Leuven, UZL</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bart Meyns, Prof. Dr.</last_name>
      <phone>0032-16 34 42 60</phone>
      <email>bart.meyns@uzleuven.be</email>
    </contact>
    <contact_backup>
      <last_name>Klaartje Van den Bossche</last_name>
      <phone>0032-16 34 21 60</phone>
      <email>klaartje.vandenbossche@uzleuven.be</email>
    </contact_backup>
    <investigator>
      <last_name>Bart Meyns, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Düsseldorf, Department of Cardiovascular Surgery</name>
      <address>
        <city>Düsseldorf</city>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Artur Lichtenberg, Prof. Dr.</last_name>
      <phone>0049 (0) 2118118331</phone>
      <email>Artur.Lichtenberg@med.uni-duesseldorf.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hannover Medical School</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samir Sarikouch, PD MD</last_name>
      <phone>049511532</phone>
      <phone_ext>5567</phone_ext>
      <email>sarikouch.samir@mh-hannover.de</email>
    </contact>
    <investigator>
      <last_name>Axel Haverich, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera di Padova, U.O.C. di Cardiochirurgia Pediatrica e Cardiopatie Congenite</name>
      <address>
        <city>Padova</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Giovanni Stellin, Prof. Dr.</last_name>
      <phone>+39 0498 212427</phone>
    </contact>
    <contact_backup>
      <last_name>Massimo Padalino, Dr.</last_name>
      <phone>+39 0498 212424</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Leids Universitair Medisch Centrum, LUMC</name>
      <address>
        <city>Leiden</city>
        <zip>2333</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark G Hazekamp, Prof. Dr.</last_name>
      <phone>0031-31 71 526 2348</phone>
      <email>m.g.hazekamp@lumc.nl</email>
    </contact>
    <investigator>
      <last_name>Mark G Hazekamp, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Clinic de Barcelona, Cardiovascular Surgery administrative area</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>José L Pomar, Prof. Dr.</last_name>
      <phone>+34 (0) 93 227 1792</phone>
      <email>jlpomar@clinic.ub.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kinderspital Zürich</name>
      <address>
        <city>Zürich</city>
        <zip>8032</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Hübler, Prof.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Brompton and Harefield National Health Service Trust</name>
      <address>
        <city>London</city>
        <zip>SW3 6NP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Pepper, Prof. Dr.</last_name>
      <email>j.pepper@rbht.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>John Pepper, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://arise-clinicaltrial.eu/home.html</url>
    <description>ARISE Website</description>
  </link>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 27, 2015</study_first_submitted>
  <study_first_submitted_qc>August 17, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 19, 2015</study_first_posted>
  <last_update_submitted>January 31, 2018</last_update_submitted>
  <last_update_submitted_qc>January 31, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Valve Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

